Revenue Downgrade: Here's What Analysts Forecast For Coherus BioSciences, Inc. (NASDAQ:CHRS)
Revenue Downgrade: Here's What Analysts Forecast For Coherus BioSciences, Inc. (NASDAQ:CHRS)
One thing we could say about the analysts on Coherus BioSciences, Inc. (NASDAQ:CHRS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.
关于Coherus BioSciences, Inc.(纳斯达克股票代码:CHRS)的分析师,我们可以说的一件事——他们并不乐观,他们刚刚对该组织的短期(法定)预测进行了重大负面修正。他们对收入的估计进行了相当严厉的削减,这可能意味着他们承认先前的预测过于乐观。
Following the downgrade, the current consensus from Coherus BioSciences' eight analysts is for revenues of US$339m in 2024 which - if met - would reflect a substantial 61% increase on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$434m in 2024. The consensus view seems to have become more pessimistic on Coherus BioSciences, noting the sizeable cut to revenue estimates in this update.
降级之后,Coherus BioSciences的八位分析师目前的共识是,2024年的收入为3.39亿美元,如果达到,这将反映出其在过去12个月中销售额大幅增长61%。在最新估计之前,分析师预测2024年的收入为4.34亿美元。Coherus BioSciences的共识观点似乎变得更加悲观,他们指出,本次更新大幅削减了收入预期。
See our latest analysis for Coherus BioSciences
查看我们对 Coherus BioSciences 的最新分析
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240131/0-b0d4e86d50e9c5ebd4e181917a33fbdc-0-24631661588c95d849d0301bbe2aa400.png/big)
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Coherus BioSciences' rate of growth is expected to accelerate meaningfully, with the forecast 46% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 7.3% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 16% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Coherus BioSciences to grow faster than the wider industry.
我们可以从大局的角度看待这些估计值的另一种方式,例如预测如何与过去的表现相提并论,以及预测相对于业内其他公司是否或多或少看涨。从最新估计中可以明显看出,Coherus BioSciences的增长率预计将大幅加速,预计到2024年底的年化收入增长为46%,将明显快于其过去五年中每年7.3%的历史增长。相比之下,我们的数据表明,预计类似行业的其他公司(有分析师报道)的收入将以每年16%的速度增长。显而易见,尽管增长前景比最近更加光明,但分析师也预计Coherus BioSciences的增长速度将超过整个行业。
The Bottom Line
底线
The most important thing to take away is that analysts cut their revenue estimates for next year. They're also forecasting more rapid revenue growth than the wider market. Overall, given the drastic downgrade to next year's forecasts, we'd be feeling a little more wary of Coherus BioSciences going forwards.
要了解的最重要的一点是,分析师下调了明年的收入预期。他们还预测收入增长将比整个市场更快。总体而言,鉴于明年的预测大幅下调,我们将对Coherus BioSciences的未来更加警惕。
That said, the analysts might have good reason to be negative on Coherus BioSciences, given dilutive stock issuance over the past year. Learn more, and discover the 2 other risks we've identified, for free on our platform here.
尽管如此,鉴于过去一年的股票发行量呈稀释态度,分析师可能有充分的理由对Coherus BioSciences持负面看法。在此处的平台上免费了解更多,并发现我们已确定的其他 2 种风险。
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
寻找可能达到转折点的有趣公司的另一种方法是使用内部人士收购的成长型公司的免费清单,跟踪管理层是买入还是卖出。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。